BioNTech’s Bold Bet: Aiming for Breakthroughs Amid Financial Struggles
BioNTech faces financial challenges, with net profit per share dropping from €1.90 to €1.08 and revenue falling from €1.479 billion to €1.19 billion. Pivotal transition from COVID-19 vaccine production to…